15
Participants
Start Date
December 23, 2022
Primary Completion Date
May 22, 2024
Study Completion Date
August 16, 2024
NKTR-255 at 1.5 µg/kg
NKTR-255 at 1.5 µg/kg
NKTR-255 at 3.0 μg/kg
NKTR-255 at 3.0 μg/kg
NKTR-255 at 3.0/6.0 μg/kg
NKTR-255 at 3.0/6.0 μg/kg
Placebo Comparator
Commercially available 0.9% Sodium Chloride Solution for Injection (USP)
NYU Langone Medical Center, New York
Memorial Sloan Kettering Cancer Center, New York
Allegheny Health Network, Pittsburgh
Penn State Health Milton S. Hershey Medical Center, Hershey
University of Maryland, Baltimore
Novant Health Cancer Institute - Winston-Salem, Winston-Salem
Novant Health Cancer Institute, Charlotte
Winship Cancer Institute of Emory University, Atlanta
Mayo Clinic Jacksonville, Jacksonville
Vanderbilt University Medical Center, Nashville
Oncology Hematology Care Inc - Cincinnati, Cincinnati
University Of Iowa Hospitals & Clinics, Iowa City
University of Chicago Medical Center, Chicago
Saint Louis University, St Louis
Washington University School of Medicine in St. Louis, St Louis
University of Kansas Cancer Center, Fairway
University of Texas MD Anderson Cancer Center, Houston
Intermountain Healthcare, Salt Lake City
University of California San Diego, La Jolla
Fred Hutchinson/University of Washington, Seattle
UMass Memorial Medical Center, Worcester
Hackensack University Medical Center, Hackensack
Lead Sponsor
Nektar Therapeutics
INDUSTRY